Q3 FY23 Business Update Webinar Notification
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a biopharmaceutical company based in Australia, announced a business update for the quarter ending 31 March 2023. The update will be presented during a live webcast hosted by CEO Steven Lydeamore on 19 April 2023 at 11:00 AM (AEST). The company is known for its orally administered immunotherapeutic products, particularly Travelan®, which is used to prevent travelers' diarrhea. Travelan® is available in Australia and Canada as a therapeutic product and a licensed natural health product, respectively, and in the U.S. as a dietary supplement. The company is focused on developing targeted polyclonal antibodies for treating inflammatory and infectious diseases.
- Immuron is preparing to provide a business update that may positively inform investors.
- Travelan® is recognized as a preventive measure against travelers' diarrhea in multiple countries, enhancing potential market reach.
- None.
MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to advise it will provide a business update for the quarter ended 31 March 2023 (Q3 FY23).
Investors are invited to join a live webcast and Q&A hosted by Immuron CEO Steven Lydeamore on Wednesday, 19 April 2023 at 11:00am (AEST).
To register for the webinar, please click on this link:
https://us02web.zoom.us/webinar/register/WN_TpvaXZZ1QDG1FnZdXdtSGA
After registering, you will receive a confirmation email containing information about joining the webinar.
COMPANY CONTACT:
Steven Lydeamore
Chief Executive Officer
Ph:+61 (0)3 9824 5254
info@immuron.com
About Travelan®
Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.
About Travelers’ diarrhea
Travelers’ diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping, bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic Escherichia coli (ETEC) playing a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are often confused with travelers’ diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.
About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
For more information visit: http://www.immuron.com
FAQ
What is the date and time of the Immuron Q3 FY23 business update?
What is Travelan® and where is it sold?
What company is hosting a business update on April 19, 2023?
Who will host the Immuron business update webcast?
